Adverse event | Artemisinin/naphtoquine | Artemether/lumefantrine |
|---|
| | N = 62 | % | N = 61 | % |
Asthenia | 1 | 1.6 | 1 | 1.6 |
Anorexia | 3 | 4.8 | 1 | |
Nausea | 1 | 1.6 | 3 | 4.8 |
Vomitting | 1 | 1.6 | 3 | 4.8 |
Diarrhoea | 2 | 3.2 | 1 | 1.6 |
Dizziness | 2 | 3.2 | 1 | 1.6 |
Abdominal pain | 1 | 1.6 | 2 | 3.3 |
Pruritus | 1 | 1.6 | 0 | 0 |
- The most commonly reported and possibly drug-related adverse events to both combination therapies were effects on the gastrointestinal (abdominal pain, anorexia, nausea, diarrhoea and late vomiting) and central nervous system (dizziness)
- ETF = Early treatment failure LCF = Late clinical failure LPF = Late parasitological failure ACPR = Adequate Clinical and parasitological response. As shown in Table 2, the ACPR was 100% for AN and AL on day 14 after treatment. On day 28 cure rates were 100% (62 of 62) and 98.4% (60 of 61) for participants receiving AN and AL, respectively. When the efficacy results were corrected for PCR results, an ACPR of 100% was observed with AL (61/61). This difference between treatment arms was not statistically significant (p > 0.05)
